Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Study Comparing Lenalidomide and Subcutaneous Daratumumab (R-Dara SC) vs Lenalidomide and Dexamethasone (Rd) in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy

NCT03993912 is registered in ClinicalTrials.gov with University Hospital, Lille as lead sponsor.

NCT NCT03993912
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03993912 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Study Comparing Lenalidomide and Subcutaneous Daratumumab (R-Dara SC) vs Lenalidomide and Dexamethasone (Rd) in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy
Lead sponsor
University Hospital, Lille
Phase
Phase 3
Overall status
Completed
Start date
October 17, 2019
Completion date
August 28, 2026
Enrollment
294 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma